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ies investigating outcomes of postmenopausal womenwith acute coronary syndromes (ACS) in relation tomen-
opausal age are lacking.
Methods:Weanalyzed the 1-year outcome of 373womenwith acutemyocardial infarction enrolled in the Ladies
ACS study. All patients underwent coronary angiography, with corelab analysis. Menopause questionnaires were
administered during admission. Menopausal age below the median of the study population (50 years) was de-
ﬁned as “early menopause”. The composite 1-year outcome included all-cause mortality, recurrent myocardial
infarction and stroke.
Results: Themean age at index ACSwas 73 years (IQR 65–83) for womenwith earlymenopause, and 74 (IQR 65–
80) for those with late menopause. Patients with early menopause had more prevalent chronic kidney disease
(12.8% vs 5.9%, p= 0.03), whereas there were no differences in all other clinical characteristics, extent of coro-
nary disease at angiography (as assessed by Gensini and SYNTAX scores), as well as interventional treatments.
Within 1 year, women with late menopause had signiﬁcantly better outcome as compared with those with
early menopause (6.5% vs 15.3%, p= 0.007). At logistic regression analysis, late menopause was independently
associatedwith better outcome (OR 0.28; 95% CI 0.12–0.67; p= 0.004).With each year's delay in themenopause
the adjusted risk decreased by 12% (OR 0.88, 0.77–0.99, p= 0.040).
Conclusion:Despite comparable clinical and angiographic characteristics,womenwith latemenopausal age expe-
rience better outcomes after an ACS as compared with those with early menopause.






Age at onset of menopause has been shown to be an independent
predictor of subsequent cardiovascular events and mortality, with
later menopause associated with lower risk [1–6]. Among the potential
mechanism of this association are genetic factors that would beOspedale A. Manzoni, Via dell'
.responsible of both early reproductive and cardiovascular aging [7],
early withdrawal of the vascular protective effect of estrogen [8,9],
and a role of the classical cardiovascular risk factors which might be
the cause or the consequence of early reproductive failure [10,11]. How-
ever, clinical studies investigating the outcomes of postmenopausal
women with acute coronary syndrome (ACS) in relation to their age
at menopause onset are lacking. In the report of the Ladies ACS study,
we showed that age at menopause was not related to the extent of cor-
onary artery disease among postmenopausal women with an ACS [12].
In the present paper, we report the one-year follow-up of that cross-
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ciated with clinical outcome after an ACS.
2. Methods
The Ladies ACS study (NCT01997307) is a prospective, multicenter investigation in-
cluding postmenopausal women and age-matched men with an ACS, stratiﬁed in 4 ten-
year age groups (55–64, 65–74, 75–85 and N85 years) with a sampling ratio of 2:1 of
women vs men. The details of the study design have been described previously [12]. The
focus of the study was angiographic, with a corelab analysis of the angiograms collected
at the study sites. However, the investigators of 6 out of 10 participating centers (contrib-
uting with 94% of the study population) volunteered to perform a one-year follow-up to
investigate the relation between their clinical and angiographic ﬁndings and outcome.
2.1. Inclusion criteria
For a patient to be eligible, the following characteristics were required: a) symptoms
suggestive of acute myocardial ischemia; b) a typical rise and fall in serum troponin levels
[13], and c) electrocardiographic signs of myocardial ischemia. Such characteristics are
consistent with the diagnosis of acute myocardial infarction (MI), either with or without
ST-segment elevation. All study participants had a clinical indication to coronary angiogra-
phy as per routine in the participating centers. There were no exclusion criteria, besides a
patient's inability to recall reproductive and menopause history, and inability or unwill-
ingness to provide informed consent to the study. Fertile life and menopause history
was collected using a speciﬁc questionnaire.
2.2. Data collection
A web-based case report form (Mediolanum Cardio Research, Milan, Italy) was used
to collect data on the personal characteristics (age, bodyweight, bodymass index), the rel-
evant risk factors for coronary disease (hypertension, diabetesmellitus, smoking, dyslipid-
emia, physical activity), prior clinical history (MI, coronary angioplasty, bypass surgery,
and stroke), prognostically relevant variables (such as serum creatinine, chronic kidney
disease, blood haemoglobin, left ventricular ejection fraction [LVEF]); characteristics of
the acute coronary syndrome (electrocardiographic changes, troponin elevation, Killip
class, heart rhythm); angiographic data, coronary revascularization procedures and med-
ications during admission, as well as drugs prescribed at discharge.
Coronary angiograms collected at the participating centers were assessed by an inde-
pendent core laboratory blinded to patients' age, sex, ST-segment status, and clinical data
(European Imaging Laboratory, Rome, Italy). The extent of coronary atherosclerosis at an-
giographywasquantiﬁed for each patient using theGensini score,which includes both an-
giographically nonsigniﬁcant and signiﬁcant stenoses [14,15]. Diagnostic angiograms
were also scored according to the SYNergy between percutaneous coronary intervention
with TAXus and cardiac surgery (SYNTAX) score algorithm, a comprehensive anatomic as-
sessment of the coronarydisease derived fromvarious preexisting anatomic classiﬁcations
[16].
Follow-up datawere collected by hospital visits or telephone calls. The studywas con-
ducted in conformity with the Declaration of Helsinki.
2.3. Menopause questionnaire
Women's questionnaire included age atﬁrst and last menstrual period, the number of
full-term pregnancies, use of oral contraceptives, ongoing and past hormone replacement
therapy and whether a hysterectomy and/or oophorectomy had been performed. Age at
menarche was deﬁned as the age at the ﬁrst menstrual period. Age atmenopause was de-
ﬁned as age at last menstrual period. Duration of reproductive life span was generated by
subtracting age at menarche from age at menopause [17].
2.4. Endpoints
The composite study outcomewas the 1-year occurrence of all-cause death, recurrent
MI (same deﬁnition used for the index ACS event) and stroke. As secondary outcome, we
considered also re-hospitalization for cardiovascular causes (including severe recurrent is-
chemia, heart failure, cardiac arrhythmia and systemic embolism).
2.5. Statistical analysis
We compared demographics, clinical and angiographic characteristics according to
age atmenopause, dichotomizedby themedian of 50 years, which corresponds to theme-
dian age at menopause in Europe [18]. Continuous variables were compared using the
Student t-test for symmetric variables and the Mann-Whitney test by ranks for skewed
variables; the results are presented as means and standard deviations (SD) or medians
and 25th and 75th percentile, respectively. Discrete variables were compared using the
chi squared test and presented as absolute and relative frequencies per category. The
exact date of post-discharge events within one-year follow up was not available. There-
fore, we ﬁtted a multivariable logistic regression model in order to derive the odds ratio
(ORs) and the 95% conﬁdence interval (CI) of the composite event, adjusted for the follow-
ing variables: age, LVEF, chronic kidney disease, age atmenopause (tested as dichotomous
and continuous variable) and SYNTAX score. All analyses were performed using the pack-
age STATA/SE 14 (StataCorp LP, College Station, TX).3. Results
3.1. Baseline characteristics
The study population consists of 373 patients, and the median age
at menopause was 50 years: 203 women had had menopausal age of
≤50 years, and 170 ≥ 50 years. The mean menopausal age was 47 years
in women with early menopause, as compared with 53 years in those
with late menopause (p b 0.001). Menopause was physiological in 79%
of women with early menopause, as compared with 97% of those with
late menopause (p b 0.001). Hormone replacement therapy was as-
sumed by 18% of women with early menopause as compared with
9.4% of those with late menopause (p= 0.021).
As shown in Table 1, the baseline clinical characteristics, including
cardiovascular risk factors, prior medical history and clinical presenta-
tion at index ACS events were similar in the two menopausal age
groups, except for chronic kidney dysfunction, which was more fre-
quent amongwomenwith early menopause. Womenwith early meno-
pause were taking signiﬁcantly more ACE-inhibitors. The coronary
angiographic ﬁndings and revascularization procedures were also simi-
lar between menopausal age groups, as were the treatments adminis-
tered at discharge (Table 2).
3.2. One-year outcomes
As reported in Table 3, the rate of the aggregate outcome events was
signiﬁcantly lower in women with late menopause. All individual end-
point components (all-cause mortality, recurrent MI and stroke) were
numerically lower in women with late menopause. The adjusted odds
ratios for the composite endpoint of death, MI and stroke (OR 0.28;
95% CI 0.12–0.67; p= 0.004), as well as for the composite endpoint in-
cluding rehospitalization for cardiovascular causes (OR 0.54; 95% CI
0.31–0.94, p = 0.026) were signiﬁcantly reduced for women with late
menopause. The association of late menopause with better outcome
was conﬁrmed at a sensitivity analysis including only womenwith nat-
ural menopause: OR 0.25; 95% C.I. 0.10–0.65, p = 0.004 for the primary
outcome, andOR0.41; 95% CI 0.20–0.84, p = 0.015 including cardiovas-
cular rehospitalizations. A further sensitivity analysis excluding patients
with chronic kidney dysfunction yielded similar results. When age at
menopause vas modeled as a continuous variable, each year's delay in
the menopause was associated with a 12% reduction in risk of the com-
posite outcome event (OR 0.88, 0.77–0.99, p = 0.04).
4. Discussion
The LADIES ACS study was aimed at investigating whether age at
menopause is associated with the extent of angiographically quantiﬁed
coronary atherosclerosis in the post-menopausal decades [12]. The an-
swer was clearly that it is not: the extent of coronary disease increased
with aging, but didn't show any correlation with menopausal age, both
in terms of the overall burden of coronary lesions (Gensini score), and in
terms of critical lesions (SYNTAX score). However, despite the similarity
in coronary atherosclerosis, the present follow-up data show that
womenwith earliermenopausehad signiﬁcantlyworse 1-year outcome
as compared with those with age at menopause above median.
The higher cardiovascular risk associated with early menopause,
particularly in terms of cardiovascular mortality, has been shown in a
longitudinal study of 12,115 postmenopausal women living in Utrecht,
Netherlands, aged 50–65 years at enrolment in a breast cancer screen-
ing project [1]. In that study, with each year's delay in the menopause
the cardiovascularmortality risk decreased by 2%. That ﬁndingwas con-
ﬁrmed by subsequent metanalyses of longitudinal studies of women
without overt heart disease at baseline [2–5]. A recent report of the
U.S. National Health and Nutrition Examination Survey also showed
that a 1-year increase in the reproductive duration was associated
Table 1
Baseline characteristics stratiﬁed according to menopausal age.
Variable All patients
n = 373
Menopausal age ≤ 50
n = 203
Menopausal age N 50
n = 170
p Value
Age (y)a 73 (65–82) 73 (65–83) 74 (65–80) 0.79
Age at menopause (years)a 50 (47–53) 47 (45–50) 53 (52–55) b0.001
Fertility life span (years)a 38 (34–40) 34 (31–37) 41 (39–42) b0.001
Age from menopause to ACS (years)a 23 (15–32) 27 (19–37) 19 (12–27) b0.001
Body mass index (Kg/m2)a 25.8 (23.0–29.3) 25.9 (22.9–29.4) 25.7 (23.1–29.3) 0.76
Hemoglobin (gr/dL)a 12.8 (11.6–14.0) 12.7 (11.6–14.0) 12.8 (11.6–13.8) 0.62
Creatinine (mg/dL)a 0.81 (0.7–1.06) 0.84 (0.7–1.08) 0.80 (0.7–1.05) 0.36
Creatinine clearance (mL/min)a 72.6 (53.6–88.4) 70.7 (52.5–88.4) 74.5 (54.5–88.2) 0.39
Left ventricle ejection fractiona 50 (40–55) 50 (40–55) 50 (40–55) 0.58
Hypertension 295 (79.1) 164 (80.8) 131 (77.1) 0.24
Hypercholesterolemia 215 (57.6) 115 (56.6) 100 (58.8) 0.41
Smoking habit 118 (31.6) 64 (31.5) 54 (31.8) 0.43
Family history of CAD 73 (19.6) 43 (21.2) 30 (17.6) 0.28
Diabetes mellitus 104 (27.9) 61 (30.0) 43 (25.3) 0.24
Chronic kidney disease 36 (9.6) 26 (12.8) 10 (5.9) 0.03
COPD 22 (5.9) 12 (5.9) 10 (5.9) 0.43
Prior stroke or TIA 31 (8.3) 19 (9.4) 12 (7.1) 0.30
Peripheral artery disease 46 (12.3) 26 (12.8) 20 (11.8) 0.41
Malignancies 32 (8.6) 16 (7.9) 16 (9.4) 0.38
Prior MI 52 (13.9) 30 (14.8) 22 (12.9) 0.37
Prior angina 59 (15.8) 38 (18.7) 21 (12.3) 0.10
Prior revascularization
Prior PCI 52 (13.9) 29 (14.3) 23 (13.5) 0.42
Prior CABG 27 (7.2) 13 (6.4) 14 (8.2) 0.35
Diagnosis
STEMI 189 (50.7) 104 (51.2) 85 (50.0) 0.81
NSTEMI 184 (49.3) 99 (48.8) 85 (50.0)
Killip class presentation
I 304 (81.5) 164 (80.8) 140 (82.3) 0.89
II 36 (9.6) 19 (9.4) 17 (10.0) 0.96
III 24 (6.4) 14 (6.9) 10 (5.9) 0.91
IV 5 (1.3) 4 (2.0) 1 (0.6) 0.51
Cardiovascular medications taken during the last 30 days prior to hospital admission
Beta-blockers 143 (38.3) 76 (37.4) 67 (39.4) 0.19
Acetil salicilic acid 131 (51.1) 71 (34.9) 60 (35.3) 0.27
P2Y12 inhibitors 40 (10.7) 24 (11.8) 16 (9.4) 0.29
ACE-inhibitors 113 (30.1) 75 (36.9) 38 (22.3) 0.01
Angiotensin receptor antagonists 40 (10.7) 21 (10.3) 19 (11.2) 0.49
Statins 130 (34.8) 68 (33.5) 62 (36.5) 0.16
Diuretics 126 (33.8) 76 (37.4) 50 (29.4) 0.16
Calcium channel blockers 64 (17.1) 33 (16.3) 31 (18.2) 0.23
Oral anticoagulants 26 (7.0) 14 (6.9) 12 (7.1) 0.32
Nitrates 33 (8.8) 20 (9.8) 13 (7.6) 0.29
Anti-arrhythmics 15 (4.0) 9 (4.4) 6 (3.5) 0.32
CABG= coronary artery bypass grafting; CAD= coronary artery disease; CKD= chronic kidney disease; COPD= chronic obstructive pulmonary disease; MI=myocardial infarction;
NSTEMI= non-ST-elevation myocardial infarction; PCI= percutaneous coronary intervention; STEMI= ST-elevation myocardial infarction. TIA= transient ischemic attack.
a Expressed as median and interquartile range. Categorical data are expressed as numbers and percentage.
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[19].
The pathophysiological mechanism of this association remains dis-
puted so far. Since modiﬁable risk factors have been shown to account
for 90% of MIs in both sexes [20], the relation of menopausal age with
the subsequent evolution of these risk factors has been investigated. In
an analysis derived from the EPIC-INTERACT study, women with an
early age at menopause onset (deﬁned as b42 years) were at higher
risk of developing type-2 diabetes [10]. However, a study in a large
population-based cohort in the Netherlands showed only a modest im-
pact of menopause on risk factors [21]. An opposite view that a worse
heart disease proﬁle determines an earlier menopause was suggested
by data coming from Framingham Heart study [11]. In that analysis,
695 women whowere premenopausal at the study entry had their car-
diovascular risk factors measured and were followed until the time of
their natural menopause, showing that every 1% increase in premeno-
pausal Framingham risk score was associated with a decrease in meno-
pausal age of 1.8 years.
We studied the coronary angiograms of postmenopausal women
with acute MI, of which 85% were at their ﬁrst episode [12], and corre-
lated this data with menopausal age, and prospectively with one-yearoutcome. We found no material differences in baseline characteristics,
except for the presence of chronic kidney dysfunction, a powerful prog-
nostic indicator and marker of macro- and microvascular damage [22],
which was more frequent among women with early menopause.
Whereas age at menopause was not associated with the extent of coro-
nary disease at angiography [12], women with earlier menopause
showed signiﬁcantly worse outcome. All the ischemic components of
the composite outcomewere more frequent amongwomenwith earlier
menopause, except rehospitalizations. Importantly, menopausal age
showed an association with adverse cardiovascular outcome indepen-
dent of other powerful predictors, such as age, LVEF and SYNTAX score.
These ﬁndings are consistent with the results of longitudinal studies in
women without known cardiovascular disease at baseline, and showing
an increased risk of subsequent cardiovascular mortality among women
with early onsetmenopause [1–6]. Earlymenopause has also been found
associated with an increased risk of developing heart failure later in life
[23–25]. In the present study,womenwith earlymenopausewere taking
signiﬁcantly more ACE-inhibitors prior to admission, which may be an
indirect index of prior heart failure symptoms, although baseline LVEF
was the same in both groups. Altogether, these data consolidate the con-
cept that early menopause is associated with worse cardiovascular
Table 2
Angiographic and interventional data stratiﬁed according to classes at menopause.
Variable All patients
n = 373
Menopausal age ≤ 50
n = 203
Menopausal age N 50
n = 170
p Value
Radial access site 298 (79.9) 160 (78.8) 138 (81.2) 0.77
Gensini scorea 46 (24–68) 47 (27–67) 44 (22–68) 0.50
Gensini scoreb 49.7 ± 31.5 50.2 ± 29.9 49.2 (33.3) 0.78
SYNTAX scorea 12 (6–21) 12 (7–22) 12 (5–21) 0.89
SYNTAX scoreb 14.9 ± 12.4 14.9 ± 11.9 15.0 ± 12.8 0.94
Coronary revascularization
PCI 267 (71.6) 153 (75.4) 114 (67.1) 0.24
CABG 13 (3.5) 5 (2.5) 8 (4.7)
Total number of lesions treateda 1 (1–1) 1 (1–1) 1 (1–1) 0.75
Total number of stents implanteda 1 (0–1) 1 (0–1) 1 (0–1) 0.27
Drugs at discharge
Beta-blockers 304 (81.5) 163 (80.3) 141 (82.9) 0.47
Acetil salicilic acid 348 (93.3) 189 (93.1) 159 (93.5) 0.42
P2Y12 inhibitors 309 (82.8) 171 (84.2) 138 (81.2) 0.43
Clopidogrel 162 (43.4) 83 (40.9) 79 (46.5)
Prasugrel 70 (18.8) 44 (21.7) 26 (15.3)
Ticagrelor 77 (20.6) 44 (21.7) 33 (19.4)
ACE-inhibitors 248 (66.5) 141 (69.5) 107 (62.9) 0.14
Angiotensin receptor antagonists 85 (22.8) 43 (21.2) 42 (24.7) 0.15
Statins 336 (90.1) 183 (90.1) 153 (90) 0.40
Diuretics 169 (45.3) 89 (43.8) 80 (47.1) 0.44
Calcium channel blockers 74 (19.8) 34 (16.7) 40 (23.5) 0.15
Oral anticoagulants 39 (10.5) 19 (9.4) 20 (11.8) 0.39
Oral anti-diabetics 53 (14.2) 33 (16.3) 20 (11.8) 0.21
Insulin 41 (11.0) 21 (10.2) 20 (11.8) 0.46
Nitrates 48 (12.9) 25 (12.3) 23 (13.5) 0.48
Anti-arrhythmics 23 (6.2) 13 (6.4) 10 (5.9) 0.48
Proton pump inhibitors 288 (77.2) 165 (81.3) 123 (72.3) 0.02
CABG= coronary artery bypass grafting; PCI= percutaneous coronary intervention.
Categorical data are expressed as numbers and percentage.
a Expressed as median and interquartile range.
b Expressed as mean and standard deviation.
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investigation.
According to the Ladies ACS study [12], a greater coronary athero-
sclerotic burden may not play a major causative role with respect to
the risk of developing an ACS among women with early menopause.
However, coronary angiography is not a sensitive method for investi-
gating coronary atherosclerosis; it stands midway between the calcium
score, suitable for screening studies, and more sophisticated imaging
techniques, such as those based on intravascular ultrasounds and opti-
cal computerized tomography (OCT). The more sophisticated study so
far [26], using OCT to characterize plaquemorphology and composition
among (mostly post-menopausal) women and age-matched men with
ST-elevation MI, did not ﬁnd any quantitative or qualitative difference
between sexes, thoughwomen had signiﬁcantly smaller coronary arter-
ies, a feature that might expose them to a higher impact of vasomotor
stimuli and more frequent anginal symptoms. However, even theseTable 3
In-hospital and follow-up events according to age at menopause (median age 51 years).
Variable All patients
n = 373
Menopausal age ≤ 5
n = 203
Composite 1-year outcome
(death, myocardial infarction, and stroke)
42 (11.3) 31 (15.3)
In-hospital death 8 (2.1) 6 (3.0)
Follow-up death 13 (3.5) 9 (4.4)
In-hospital & follow-up death 21 (5.6) 15 (7.4)
In-hospital & follow-up cardiovascular death 6 (1.6) 5 (2.4)
Recurrent myocardial infarction 18 (4.8) 13 (6.4)
Stroke 3 (0.8) 3 (1.5)
Rehospitalization for cardiovascular causes 42 (11.3) 23 (11.3)
Overall outcome events 77 (20.6) 50 (24.6)
Categorical data are expressed as numbers and percentage.
a Adjusted for age, ejection fraction and SYNTAX score.
b The reference category is age at menopause b51 years.sophisticated imagingmethods are not suitable for investigating the va-
somotor and microvascular components of coronary circulation, which
may play a key role in the causation and outcome of ACS [27,28].
Whether the dynamic component of coronary circulationmay differ ac-
cording tomenopausal age, particularly inwomenwith a higher athero-
sclerotic burden may be matter for further investigation.
4.1. Limitations
The Ladies ACS study enrolled only patients aged ≥55 years. There-
fore, patients with very young menopausal age and with an ACS before
55 years were not included. The study was an investigation on angio-
graphically assessed coronary atherosclerosis, including only women
undergoing coronary angiography because of an ACS with ischemic
ECG changes and elevated troponin levels. Therefore, our conclusion is
limited to this study population which, however, represents the large0 Menopausal age N 50
n = 170
p Value Adjusted odds
ratio (95% C.I.)
p Valuea
11 (6.5) 0.007 0.28 (0.12–0.67)b 0.004
2 (1.2) 0.24 0.36 (0.06–1.96) 0.24
4 (2.3) 0.27 0.71 (0.19–2.71) 0.63
6 (3.5) 0.11 0.50 (0.17–1.50) 0.22
1 (0.6) 0.25 0.32 (0.08–1.29) 0.11
5 (2.9) 0.07 0.24 (0.06–0.95) 0.04
0 0.07 – –
19 (11.2) 0.27 0.97 (0.39–2.37) 0.95
27 (15.9) 0.04 0.54 (0.31–0.94)b 0.03
12 S. Savonitto et al. / International Journal of Cardiology 259 (2018) 8–13majority of ACS patients in Europe. Themost severe cases (such as those
with out of hospital cardiac arrest), and also patients with unstable an-
gina and no troponin elevations (such asmany of thosewith variant an-
gina or puremicrovascular angina) have not been included in the Ladies
ACS population. However, our results are in the same direction of longi-
tudinal studies with no overt cardiac disease at baseline [1–6], and rein-
force their conclusion of an increase cardiovascular risk associated with
younger menopausal age.
We had no information on the date of the follow-up events. Consid-
ering the short follow-up, the implications of this are however limited.
The limits of menopause reporting using questionnaires several
years after actual menopause have been quantiﬁed within one year of
variation in recall studies [29–31], and appear acceptable for the pur-
poses of the present analysis.
5. Conclusions
Women reporting menopausal age belowmedian have signiﬁcantly
worse outcomes within one year after an ACS, as compared with
women with later menopause. This worse outcome is not explained
by differences in cardiovascular risk factors, prior cardiovascular events,
age at index ACS, severity of coronary angiographic ﬁndings and ejec-
tion fraction. The pathophysiological reasons behind these ﬁndings
should be further investigated using functional testing of the endothe-
lium and microvasculature beyond the limits of current imaging
methods [28].
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